Filgrastim Biosimilars Demonstrate $15 Million Cost Savings Potential in Cancer Care
Key Insights
A simulated study from Saudi Arabia found that substituting filgrastim with its biosimilar pegfilgrastim could save nearly $3 million for 4,000 patients over 6 chemotherapy trials.
The research demonstrated that biosimilar adoption could provide supportive care for an additional 9,244 patients with the initial savings, and over 32,000 patients when compared to reference products.
With global cancer (search) medication spending exceeding $223 billion in 2023 and projected to reach $409 billion by 2028, biosimilars offer significant cost-reduction opportunities.
A new simulated study from Saudi Arabia has quantified the substantial cost-saving potential of filgrastim biosimilars in cancer (search) care, revealing savings of nearly $3 million for 4,000 patients undergoing chemotherapy treatment. The research examined substitution of filgrastim (Neupogen; Amgen) with its biosimilar pegfilgrastim (Udencya (search); Coherus (search)) across 6 chemotherapy trials, demonstrating significant financial benefits without compromising treatment efficacy.
Quantified Savings and Patient Access Benefits
The study found that biosimilar adoption generated savings totaling nearly $3 million, which enabled additional supportive care for 9,244 patients. When researchers compared the biosimilar to the reference product, the cost reduction reached up to $12 million, allowing supportive care expansion to more than 32,000 patients.
These findings come at a critical time when global cancer (search) medication spending exceeded $223 billion in 2023 and is projected to eclipse $409 billion by 2028. The research suggests that with only one biosimilar generating $15 million in savings, larger oncology medication classes could offer substantial additional cost reductions.
Implications for Healthcare Systems
The study's authors noted that with a population 10 times that of Saudi Arabia, the United States could achieve exponentially larger savings through increased biosimilar adoption. The research highlighted that biosimilars offer a cost-effective treatment method that simultaneously increases access to care for more patients.
However, the implementation of biosimilars faces practical challenges. Selection of a biosimilar requires addition to formulary through a Pharmacy and Therapeutics (P&T) committee, and with numerous products available at varying prices, choosing appropriate biosimilars can be complex. Factors including regulatory approval, availability, and substitution capabilities must be considered during the selection process.
Implementation Considerations
The research emphasized that successful biosimilar adoption requires proper training of entire pharmacy staff to build trust and drive meaningful change that could save institutions and patients millions of dollars. When both originator and biosimilar products are available at one location, proper storage protocols are crucial to prevent inadvertent administration of incorrect medications.
The study authors recommended introducing policies that promote biosimilar selection and establishing contingency plans for potential supply chain interruptions to streamline the selection process. They noted that while adding biosimilars to formularies can seem daunting, formulary management teams should take initiative to incorporate appropriate biosimilars to reduce patient expenses and increase institutional savings.
Filgrastim is commonly prescribed to boost white blood cell counts in patients undergoing chemotherapy, making it a critical component of cancer (search) supportive care. The research demonstrates that biosimilar versions maintain treatment efficacy while providing substantial cost advantages over reference biologics, which have historically been associated with high healthcare spending.